Clinical trial NCT05349474: Metformin Treatment in Progressive Multiple Sclerosis
Official title: A Double-blind, Placebo Controlled Trial of Metformin Treatment in Progressive Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: EARLY_PHASE1
Conditions: Secondary Progressive Multiple Sclerosis
Primary Progressive Multiple Sclerosis
Keywords: Multiple sclerosis
Demyelinating disease
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
First posted: 2022-04-27
Enrollment: 44
Sex: ALL
Minimum age (years): 30
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis

Detailed description: This will be a single site 1:1 randomized, placebo controlled trial of metformin treatment vs matching placebo in 44 men and women with primary progressive multiple sclerosis and secondary multiple sclerosis, without diabetes, not treated with metformin aged 30-65. The trial will last 12 months and have 3 study visits, baseline, 6 months, and 12 months. The trial will be preceded by a screening period. Over the initial 30 day titration period subjects will be titrated from 500 mg a day to 2,000 mg of metformin in increments of 500 mg every 10 days. Patients will remain on their tolerated dose and included in analysis on an intent to treat basis. Brain MRI, cognitive testing and clinical measures will be collected at baseline, month 6 and month 12. OCT will be collected at baseline and month 12. The primary outcomes are the following safety outcomes: 1) number of patients with adverse events 2) number of patients with laboratory abnormalities 3) number of patients with new T2 lesions on MRI. The secondary outcomes include reduction in localized cortical thinning on brain MRI; reduction in thalamic atrophy on brain MRI. Further exploratory outcomes include 1) improvement in SDMT-oral score, 2) improvement in CVLT-II score, 3) improvement in PACC score 4) improvement in PASAT score. Exploratory outcomes include 1) Decrease in plasma neurofilament light chain levels, 2) Reginal nerve fiber layer preservation on OCT, 3) Ganglion cell inner plexiform layer preservation, and 4) Percentage of phase rim lesions.

Eligibility criteria: Inclusion Criteria:

1. Patient signed informed consent.
2. Age 30-65
3. Primary Progressive Multiple Sclerosis or Secondary Progressive Multiple Sclerosis as defined by the 2017 McDonald Criteria
4. Intent to maintain current MS disease modifying treatment through the trial duration

Exclusion Criteria:

1. Clinical relapse in prior 12 months
2. New T2 lesion or gadolinium enhancing lesion in prior 12 months
3. Glucocorticoid use in prior six months outside the context of premedication for disease modifying treatment
4. Changes in disease modifying therapy in prior three months
5. Plans to change current disease modifying therapy
6. Contraindication to MRI, inability to tolerate MRI
7. Use of metformin for any other indication
8. Renal dysfunction (GFR \< 60)
9. Hepatic dysfunction (AST or ALT \> 1.5 x upper limit of normal)
10. B12 deficiency
11. Prior poor reaction to metformin
12. Congestive heart failure
13. Alcohol abuse
14. Metabolic acidosis
15. Females who are pregnant or who plan to become pregnant during the 12 months of enrollment, or who wish to breastfeed during any part of the 12 months of enrollment
16. Concomitant use of drugs with drug-drug interactions with metformin
17. Previous adverse effect with metformin treatment

Primary outcomes:
measure: number of patients with adverse events between baseline and conclusion (month 0 and month 12)
timeFrame: between month 0 and month 12
measure: number of patients with laboratory abnormalities between baseline and conclusion (month 0 and month 12)
timeFrame: between month 0 and month 12
measure: number of patients with new T2 lesions on MRI from baseline to conclusion (month 0 and month 12)
timeFrame: between month 0 and month 12
Secondary outcomes:
measure: a reduction in localized cortical thinning on brain MRI between baseline and conclusion (month 0 and month 12)
timeFrame: between month 0 and month 12
measure: a reduction in thalamic atrophy on brain MRI between baseline and conclusion (month 0 and month 12)
timeFrame: between month 0 and month 12
Other outcomes:
measure: improvement in SDMT-oral score between baseline and conclusion (month 0 and month 12)
timeFrame: between month 0 and month 12
measure: improvement in CVLT-II score between baseline and conclusion (month 0 and month 12)
timeFrame: between month 0 and month 12
measure: improvement in PACC score between baseline and conclusion (month 0 and month 12)
timeFrame: between month 0 and month 12
measure: improvement in PASAT score between baseline and conclusion (month 0 and month 12)
timeFrame: between month 0 and month 12
measure: decrease in plasma neurofilament light chain levels between baseline and conclusion (month 0 and month 12)
timeFrame: between month 0 and month 12
measure: decrease in number of phase rimmed lesions between baseline and conclusion (month 0 and month 12)
timeFrame: between month 0 and month 12
Locations:
city: Los Angeles
country: United States
facility: University of California, Los Angeles
state: California
Study officials:
affiliation: University of California, Los Angeles
name: Kevin R Patel, MD
role: PRINCIPAL_INVESTIGATOR
References: